A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

BACKGROUND: There is an unmet need for treatment options in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Lenalidomide plus low-dose dexamethasone is effective and generally well tolerated in Caucasian RRMM patients, but no previous study has evaluated this regimen in Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jian, Du, Xin, Jin, Jie, Cai, Zhen, Chen, Fangping, Zhou, Dao-bin, Yu, Li, Ke, Xiaoyan, Li, Xiao, Wu, Depei, Meng, Fanyi, Ai, Huisheng, Zhang, Jingshan, Wortman-Vayn, Honeylet, Chen, Nianhang, Mei, Jay, Wang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699390/
https://www.ncbi.nlm.nih.gov/pubmed/23782711
http://dx.doi.org/10.1186/1756-8722-6-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699390/
https://www.ncbi.nlm.nih.gov/pubmed/23782711
http://dx.doi.org/10.1186/1756-8722-6-41

Ejemplares similares